Biopsys places 180 Mammotome breast biopsy systems in U.S., company says.
This article was originally published in The Gray Sheet
Executive Summary
BIOPSYS MEDICAL PLACES 180 MAMMOTOME BREAST BIOPSY SYSTEMS IN U.S. since the August 1995 domestic roll-out of the product, Biopsys President and CEO Steven Gex told investors at a Piper Jaffray investment conference in Minneapolis on June 4. Over 6,000 breast cancer diagnoses have been performed with the Mammotome Biopsy System in U.S. physician's offices, hospitals, and breast imaging centers to date, Gex said. The system was formally introduced at the November 1995 Radiological Society of North America annual meeting ("The Gray Sheet" Dec. 4, 1995, p. 11).